Please provide your email address to receive an email when new articles are posted on . The phase 2 study of ALTO-203 will involve about 60 adults with MDD and evidence of anhedonia. ALTO-203 has ...
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ...
Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo.
Phase 2 study designed to evaluate the pharmacodynamic effects, pharmacokinetics, and tolerability of ALTO-203 in patients with major depressive disorder (MDD) and higher levels of anhedonia ALTO-203 ...
Another of Alto Neurosciences’ machine learning-derived, biomarker-based depression therapies has improved symptoms, boosting the case for the biotech’s precision psychiatry approach. ALTO-300 was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results